Battery Health Quantification for TDRS Spacecraft by Using Signature Discriminability Measurement

The NASA/GSFC Space Network Project Office (SN) currently operates a constellation of ten geosynchronous TDRS spacecraft launched over the past 30 years. The SN project collects up to 16.5 Gigabytes of telemetry every month. Generally, the spacecraft health and functionality are obtained by the use of real-time telemetry data for the multiple spacecraft subsystems, which are transmitted to the main ground station at the White Sands Complex in Las Cruces, NM. Recently, the SN has instituted a program of Big Data to analyze the large amounts of data using a variety of tools including Machine Learning, Artificial Intelligence, development of training sets, and a variety of mathematical modeling tools. The goal is to improve spacecraft management and obtain a more accurate prediction of the spacecraft end of life. The combination of these efforts with those of the Aerospace Corporation, which has a contract with the SN to produce yearly reliability estimates for the TDRS fleet, will be performed. This paper presents a new concept called telemetry quality quantification (TQQ) and discusses the progress that has been made in battery performance estimation for the second-generation TDRS spacecraft using a signature discriminability measures (SDM) algorithm combined with the Aerospace Corp. battery life estimation models. This activity is important because many of the TDRS fleet of spacecraft have exceeded their on-orbit design lifetime and, therefore, NASA must carefully manage the spacecraft to continue operations while avoiding an end-of-mission scenario that leaves a non-functioning spacecraft in geosynchronous orbit

Genetic mechanisms of critical illness in COVID-19.

Host-mediated lung inflammation is present1, and drives mortality2, in the critical illness caused by coronavirus disease 2019 (COVID-19). Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development3. Here we report the results of the GenOMICC (Genetics Of Mortality In Critical Care) genome-wide association study in 2,244 critically ill patients with COVID-19 from 208 UK intensive care units. We have identified and replicated the following new genome-wide significant associations: on chromosome 12q24.13 (rs10735079, P = 1.65 × 10-8) in a gene cluster that encodes antiviral restriction enzyme activators (OAS1, OAS2 and OAS3); on chromosome 19p13.2 (rs74956615, P = 2.3 × 10-8) near the gene that encodes tyrosine kinase 2 (TYK2); on chromosome 19p13.3 (rs2109069, P = 3.98 ×  10-12) within the gene that encodes dipeptidyl peptidase 9 (DPP9); and on chromosome 21q22.1 (rs2236757, P = 4.99 × 10-8) in the interferon receptor gene IFNAR2. We identified potential targets for repurposing of licensed medications: using Mendelian randomization, we found evidence that low expression of IFNAR2, or high expression of TYK2, are associated with life-threatening disease; and transcriptome-wide association in lung tissue revealed that high expression of the monocyte-macrophage chemotactic receptor CCR2 is associated with severe COVID-19. Our results identify robust genetic signals relating to key host antiviral defence mechanisms and mediators of inflammatory organ damage in COVID-19. Both mechanisms may be amenable to targeted treatment with existing drugs. However, large-scale randomized clinical trials will be essential before any change to clinical practice

First (National) space : (Ab)original (re)mappings of British Columbia

Before contact First Nations in what is now British Columbia were not mapmakers. Territory was demarcated experientially, by genealogy, oral narrative, ceremony, and the social arts. Since contact, however, and especially since the beginning of the comprehensive claims process in the early 1970s, First Nations have become mapmakers — not because they especially wanted to but because they had to. They have recognized that cartography — whether in court, at the treaty table, or for pedagogical purposes — is a way of validating Aboriginal title and rights. They have also recognized, however, that committing their geographies to maps is a risky endeavour. Much of what distinguishes First Nations' geographical space does not translate well in a cartographic register and Euro-Canadians generally lack the cultural equipment to interpret and evaluate what does. This dissertation tries to open a space where translation can occur. Drawing on both Native and ethnographic sources and guided by my experience and some of the postcolonial literature, I show that First Nations' maps are both a record of an encounter that has always turned on the ability of one side to dominate the representational terrain of the other and a window on a world that most non-Natives have hitherto apprehended only in the faintest outline. The questions raised by this dissertation, then, are of a theoretical sort, but the answers are matters of fact and future practice. Land claims, if they are about anything at all, are about the struggle over geography — both the terrestrial object, and the perspective through which that object is territorialized — for Aboriginal title and rights, if recognized by law, mean nothing without the territories to which they refer. At issue is not whether the 'map of First Nations' is more true than the 'map of British Columbia' — though I will defend such a claim — but whether or not, in mirroring one against the other, a space of mutual understanding can be reached.Arts, Faculty ofGeography, Department ofGraduat

Utilization of Unsupervised Anomalies Detector as a Tool for Managing the TDRS Constellation at GSFC

NASAs Goddard Space Flight Center (GSFC) operates a constellation of ten geosynchronous Tracking and Data Relay Satellites (TDRS). The mission of the TDRS constellation is to provide relay communications from low-earth orbiting spacecraft to the primary ground station at the White Sands Complex in Las Cruces, New Mexico. Major customers include the International Space Station and Hubble Space Telescope. The NASA Space Network project office at GSFC manages the constellation of spacecraft. The constellation is over 30 years old, and a wide range of technologies and manufacturing techniques are represented on-orbit. Since 1983, the TDRS constellation has recorded thousands of gigabytes of telemetry data. Spacecraft telemetry data has changed throughout the three generations of TDRS spacecraft, however each spacecraft has the same basic functions with some generational enhancements. The constellation includes several spacecraft that have significantly outlived the manufacturer's projected lifetime. This has provided NASA with a significant benefit in terms of return on investment, however it places a burden on efficient management of the assets for maximum life without permitting a TDRS spacecraft to become stranded in its geosynchronous orbital slot. Consequently, the highest level of attention is paid to systems whose failure could strand a TDRS spacecraft in orbit. In this paper, we proposed two stages of analyzing spacecraft anomalies using data mining (DM) to enhance on-going predictions of spacecraft life, subsystem performance, and analysis of subsystem anomalies. The first stage conducts the unsupervised anomaly detector to detect potential anomalies in real-time telemetry data. The second stage introduced telemetry weight (TW) to each telemetry parameter to determine which parameter caused the strongest anomaly. We will present case studies of some of these analyses and how the data can impact decisions on the management of the constellation

Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury A Randomized Clinical Trial

IMPORTANCE: Sepsis-associated acute kidney injury (AKI) adversely affects long-term kidney outcomes and survival. Administration of the detoxifying enzyme alkaline phosphatase may improve kidney function and survival. OBJECTIVE To determine the optimal therapeutic dose, effect on kidney function, and adverse effects of a human recombinant alkaline phosphatase in patients who are critically ill with sepsis-associated AKI. DESIGN, SETTING, AND PARTICIPANTS: The STOP-AKI trial was an international (53 recruiting sites), randomized, double-blind, placebo-controlled, dose-finding, adaptive phase 2a/2b study in 301 adult patients admitted to the intensive care unit with a diagnosis of sepsis and AKI. Patients were enrolled between December 2014 and May 2017, and follow-up was conducted for 90 days. The final date of follow-up was August 14, 2017. INTERVENTIONS: In the intention-to-treat analysis, in part 1 of the trial, patients were randomized to receive recombinant alkaline phosphatase in a dosage of 0.4 mg/kg (n = 31), 0.8 mg/kg (n = 32), or 1.6 mg/kg (n = 29) or placebo (n = 30), once daily for 3 days, to establish the optimal dose. The optimal dose was identified as 1.6 mg/kg based on modeling approaches and adverse events. In part 2, 1.6 mg/kg (n = 82) was compared with placebo (n = 86). MAIN OUTCOMES AND MEASURES: The primary end point was the time-corrected area under the curve of the endogenous creatinine clearance for days 1 through 7, divided by 7 to provide a mean daily creatinine clearance (AUC(1-7) ECC). Incidence of fatal and nonfatal (serious) adverse events ([S]AEs) was also determined. RESULTS: Overall, 301 patients were enrolled (men, 70.7%; median age, 67 years [interquartile range {IQR}, 59-73]). From day 1 to day 7, median ECC increased from 26.0 mL/min (IQR, 8.8 to 59.5) to 65.4 mL/min (IQR, 26.7 to 115.4) in the recombinant alkaline phosphatase 1.6-mg/kg group vs from 35.9 mL/min (IQR, 12.2 to 82.9) to 61.9 mL/min (IQR, 22.7 to 115.2) in the placebo group (absolute difference, 9.5 mL/min [95% CI, -23.9 to 25.5]; P = .47). Fatal adverse events occurred in 26.3% of patients in the 0.4-mg/kg recombinant alkaline phosphatase group; 17.1% in the 0.8-mg/kg group, 17.4% in the 1.6-mg/kg group, and 29.5% in the placebo group. Rates of nonfatal SAEs were 21.0% for the 0.4-mg/kg recombinant alkaline phosphatase group, 14.3% for the 0.8-mg/kg group, 25.7% for the 1.6-mg/kg group, and 20.5% for the placebo group. CONCLUSIONS AND RELEVANCE: Among patients who were critically ill with sepsis-associated acute kidney injury, human recombinant alkaline phosphatase compared with placebo did not significantly improve short-term kidney function. Further research is necessary to assess other clinical outcomes